KBY Biotech Indexv0.0.34
Search
← Pipeline|Adagralucimab

Adagralucimab

NDA/BLA
CRB-2887
By Caribou Bio
Source: Trial-derived·Trials: 1
Modality
ERT
MOA
RAS(ON)i
Target
CD123
Pathway
Lipid Met
RettLN
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
~Jun 2018
→ ~Sep 2019
NDA/BLA
Dec 2019
→ Sep 2026
NDA/BLACurrent
NCT04971313
1,428 pts·LN
2019-12→2026-09·Not yet recruiting
1,428 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-09-145mo awayPh3 Readout· LN
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-09-14 · 5mo away
LN
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04971313NDA/BLALNNot yet recr...1428UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
REG-7737RegeneronPreclinicalCD123WRNi
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
IvotuximabMadrigal PharmaPhase 2CD123CFTRmod
ZorizumabBeamApprovedCD123AuroraAi
CGO-2579CG OncologyApprovedTIGITRAS(ON)i